Communiqués Unity Biotechnology, Inc.

Actions

UBX

US91381U2006

Temps réel estimé Cboe BZX Autres places de cotation 15:59:05 18/06/2024			Varia. 5j.	Varia. 1 janv.
1,355 ^USD	-1,81%		-15,91%	-28,98%

14/05	Unity Biotechnology, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
23/04	Unity Biotechnology, Inc. Annonce l'extension de l'étude clinique de phase 2b ASPIRE évaluant UBX1325 dans l'OMD	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates	14/05	AQ
UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting	25/04	AQ
UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME	23/04	AQ
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates	15/04	AQ
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss	06/02	AQ
UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME	12/12	AQ
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates	13/11	AQ
UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds	10/11	AQ
UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration	27/09/23	AQ
UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates	08/08/23	AQ
UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME)	21/06/23	AQ
UNITY BIOTECHNOLOGY, INC. : Results of Operations and Financial Condition (form 8-K)	09/05/23	AQ
UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results and Business Updates	09/05/23	AQ
UNITY BIOTECHNOLOGY, INC. Change in Directors or Principal Officers (form 8-K/A)	28/04/23	AQ
UNITY BIOTECHNOLOGY, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	24/04/23	AQ
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema	24/04/23	AQ
UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema	24/04/23	AQ
UNITY BIOTECHNOLOGY, INC. : Change in Directors or Principal Officers (form 8-K)	11/04/23	AQ
Unity Biotechnology : Phase 2 ENVISION Program Update Call Presentation	27/03/23	PU
UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration	27/03/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Unity Biotechnology, Inc.

Actions

UBX

US91381U2006

Communiqués

Filtres